Cargando…

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies

Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). We conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Ahya, Dwyer, Deanna, Wu, Qi, Wang, Qin, Dowling, Catherine A., Fox, David A., Khanna, Dinesh, Poland, Gregory A., Mao-Draayer, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411370/ https://www.ncbi.nlm.nih.gov/pubmed/34483021 http://dx.doi.org/10.1016/j.vaccine.2021.08.078

Ejemplares similares

20680 Characterization of Clinical and Immunological Laboratory Features in Multiple Sclerosis Patients with COVID-19
por: Ali, Ahya S, et al.
Publicado: (2021)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis
por: Wu, Qi, et al.
Publicado: (2021)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse
por: Mills, Elizabeth A., et al.
Publicado: (2017)

Optical coherence tomography and T cell gene expression analysis in patients with benign multiple sclerosis
por: Soltys, John, et al.
Publicado: (2017)

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Piquet, Amanda L., et al.
Publicado: (2021)

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Current and Future Biomarkers in Multiple Sclerosis
por: Yang, Jennifer, et al.
Publicado: (2022)

Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations
por: Zimmermann, Michael T., et al.
Publicado: (2017)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
por: Tütüncü, Melih, et al.
Publicado: (2023)

Familial multiple sclerosis in patients with Von Hippel-Lindau disease
por: Nath, Samir R., et al.
Publicado: (2022)

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
por: Ciampi, Ethel, et al.
Publicado: (2022)

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
por: Breu, Markus, et al.
Publicado: (2023)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
por: Apostolidis, Sokratis A., et al.
Publicado: (2021)

Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration
por: Thakolwiboon, Smathorn, et al.
Publicado: (2023)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021)

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy
por: Holm, Michelle R., et al.
Publicado: (2021)

Bacterial variation in the oral microbiota in multiple sclerosis patients
por: Zangeneh, Zahra, et al.
Publicado: (2021)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study
por: Hatziantoniou, Sophia, et al.
Publicado: (2021)

Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
por: Bitzenhofer, Michaela, et al.
Publicado: (2022)

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
por: Obeid, Michel, et al.
Publicado: (2022)

Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses
por: Milo, Ron, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
por: Capone, Fioravante, et al.
Publicado: (2021)

Technical and biological variance structure in mRNA-Seq data: life in the real world
por: Oberg, Ann L, et al.
Publicado: (2012)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies
por: Habek, Mario, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b646s7h9f61mlen4uvsjsi4lpj